pharma · Multiple Myeloma · Renal Cell Cancer · CRVS
Corvus Pharmaceuticals
Corvus Pharmaceuticals clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Burlingame, USA
- Founded
- 2014
- Employees
- 48
- Programs
- 9
- Drugs
- 4
- Patents
- 14
Corvus Pharmaceuticals projects
9 ClinicalTrials.gov programs sponsored by Corvus Pharmaceuticals.
Corvus Pharmaceuticals has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CPI-006 2 mg/kg + SOC
Corvus Pharmaceuticals
Covid-19
1 trial -
Soquelitinib
Corvus Pharmaceuticals
Peripheral T-Cell Lymphoma, Not Otherwise Specified
1 trial -
Soquelitinib
Corvus Pharmaceuticals
Atopic Dermatitis
2 trials -
CPI-006
Corvus Pharmaceuticals
Non-Small Cell Lung Cancer
1 trial -
CPI-006
Corvus Pharmaceuticals
COVID-19
1 trial -
CPI-444 Capsules
Corvus Pharmaceuticals
Healthy Subjects
1 trial -
CPI-818
Corvus Pharmaceuticals
T-cell Lymphoma
1 trial -
Ciforadenant
Corvus Pharmaceuticals
Multiple Myeloma
1 trial -
Ciforadenant
Corvus Pharmaceuticals
Renal Cell Cancer
1 trial
Frequently asked questions
How many clinical projects does Corvus Pharmaceuticals have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.